From Respiratory Wiki
ANORO ELLIPTA is a combination of umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Important limitations: Not indicated for the relief of acute bronchospasm or for the treatment of asthma.
Dosage and administration
For oral inhalation only.
Maintenance treatment of COPD: 1 inhalation of ANORO ELLIPTA once daily.
Inhaler containing 2 double-foil blister strips of powder formulation for oral inhalation. One strip contains umeclidinium 62.5 mcg per blister and the other contains vilanterol 25 mcg per blister.
LABA increase the risk of asthma-related death.
Do not initiate in acutely deteriorating COPD or to treat acute symptoms
Do not use in combination with an additional medicine containing LABA because of risk of overdose.
If paradoxical bronchospasm occurs, discontinue ANORO ELLIPTA and institute alternative therapy.
Use with caution in patients with cardiovascular disorders.
Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.
Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a physician immediately if symptoms occur.
Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a physician immediately if symptoms occur.
Be alert to hypokalemia and hyperglycemia.